Department of Diagnostic Radiology, Kinki University, School of Medicine, 377-2 Ohnohigashi, Osaka-sayama, Osaka, 589-8511, Japan,
J Gastroenterol. 2014 Jan;49(1):46-56. doi: 10.1007/s00535-013-0790-5. Epub 2013 Mar 26.
Positron emission tomography (PET) is widely available and its application with 2-[(18)F] fluoro-2-deoxy-D-glucose ((18)F-FDG) in oncology has become one of the standard imaging modalities in diagnosing and staging of tumors, and monitoring the therapeutic efficacy in hepatic malignancies. Recently, investigators have measured glucose utilization in liver tumors using (18)F-FDG and positron emission tomography/computer tomography (PET/CT) in order to establish a diagnosis of tumors, assess their biologic characteristics and predict therapeutic effects on hepatic malignancies. The PET/CT with (18)F-FDG may further enhance the hepatic malignancy diagnostic algorithm by accurate diagnosis, staging, restaging and evaluating its biological characteristics, which can benefit the patients suffering from primary and metastatic hepatic tumors such as hepatocellular carcinoma (HCC), cholangiocarcinoma (CCC), and metastatic liver tumor.
正电子发射断层扫描（PET）广泛可用，其与 2-[(18)F]氟-2-脱氧-D-葡萄糖（(18)F-FDG）的联合应用已成为肿瘤诊断和分期以及监测肝恶性肿瘤治疗效果的标准成像方式之一。最近，研究人员使用(18)F-FDG 和正电子发射断层扫描/计算机断层扫描（PET/CT）测量肝肿瘤中的葡萄糖利用率，以建立肿瘤的诊断，评估其生物学特征，并预测对肝恶性肿瘤的治疗效果。(18)F-FDG 的 PET/CT 可通过准确诊断、分期、重新分期和评估其生物学特征进一步增强肝恶性肿瘤的诊断算法，这有利于原发性和转移性肝肿瘤（如肝细胞癌[HCC]、胆管细胞癌[CCC]和转移性肝肿瘤）患者。
